1. Wound infection following implant removal of foot, ankle, lower leg or patella; a protocol for a multicenter randomized controlled trial investigating the (cost-)effectiveness of 2 g of prophylactic cefazolin compared to placebo (WIFI-2 trial).
- Author
-
Sanders FRK, Penning D, Backes M, Dingemans SA, van Dieren S, Eskes AM, Goslings JC, Kloen P, Mathôt RAA, Schep NWL, Spijkerman IJB, and Schepers T
- Subjects
- Adult, Ankle, Antibiotic Prophylaxis economics, Antibiotic Prophylaxis methods, Bones of Lower Extremity injuries, Cost-Benefit Analysis, Device Removal economics, Double-Blind Method, Elective Surgical Procedures adverse effects, Elective Surgical Procedures economics, Fracture Fixation, Internal instrumentation, Humans, Infusions, Intravenous, Leg, Lower Extremity, Patella, Anti-Bacterial Agents administration & dosage, Anti-Bacterial Agents economics, Anti-Bacterial Agents therapeutic use, Bones of Lower Extremity surgery, Cefazolin administration & dosage, Cefazolin economics, Cefazolin therapeutic use, Device Removal adverse effects, Fractures, Bone surgery, Surgical Wound Infection drug therapy, Surgical Wound Infection economics, Surgical Wound Infection etiology, Surgical Wound Infection prevention & control
- Abstract
Background: Elective implant removal (IR) after fracture fixation is one of the most common procedures within (orthopedic) trauma surgery. The rate of surgical site infections (SSIs) in this procedure is quite high, especially below the level of the knee. Antibiotic prophylaxis is not routinely prescribed, even though it has proved to lower SSI rates in other (orthopedic) trauma surgical procedures. The primary objective is to study the effectiveness of a single intravenous dose of 2 g of cefazolin on SSIs after IR following fixation of foot, ankle and/or lower leg fractures., Methods: This is a multicenter, double-blind placebo controlled trial with a superiority design, including adult patients undergoing elective implant removal after fixation of a fracture of foot, ankle, lower leg or patella. Exclusion criteria are: an active infection, current antibiotic treatment, or a medical condition contraindicating prophylaxis with cefazolin including allergy. Patients are randomized to receive a single preoperative intravenous dose of either 2 g of cefazolin or a placebo (NaCl). The primary analysis will be an intention-to-treat comparison of the proportion of patients with a SSI at 90 days after IR in both groups., Discussion: If 2 g of prophylactic cefazolin proves to be both effective and cost-effective in preventing SSI, this would have implications for current guidelines. Combined with the high infection rate of IR which previous studies have shown, it would be sufficiently substantiated for guidelines to suggest protocolled use of prophylactic antibiotics in IR of foot, ankle, lower leg or patella. Trial registration Nederlands Trial Register (NTR): NL8284, registered on 9th of January 2020, https://www.trialregister.nl/trial/8284.
- Published
- 2021
- Full Text
- View/download PDF